RARE (Ultragenyx Pharmaceutical Inc.) — AI Stock Research
Research of November 4, 2026 · Healthcare / Pharmaceutical Preparations
TradeFlare's AI research teams rate RARE a HOLD. The latest price is $16.63.
The research plan
- Entry: $16.63
- Time horizon: days
The current market and stock-specific factors do not support a directional trade.
Why
The stock exhibits multiple significant red flags, including persistent unprofitability, substantial cash burn, and negative equity, all contributing to a high-risk profile. Despite the scanner's trigger related to workforce reduction, the fundamental and technical teams are not aligned bullishly, and the risk score is high. Given these factors and the neutral market regime, a HOLD recommendation is appropriate.
What could push RARE higher
- The company's workforce reduction could signal a move towards improved cost discipline and margin expansion.
- Potential for a positive fundamental shift if the company can effectively manage its cash burn and improve profitability.
- Analyst sentiment remains neutral to positive, which could provide underlying support if fundamentals improve.
Key risks for RARE
- Persistent unprofitability with negative gross, operating, and net margins.
- Significant cash burn and negative free cash flow, indicating a precarious financial position.
- Negative equity suggests liabilities exceed assets, a critical financial weakness.
What each AI research team found
Fundamental team: Bearish · valuation: speculative
Ultragenyx Pharmaceutical Inc. (RARE) exhibits significant financial distress with persistent unprofitability, a substantial cash burn, and negative equity, despite positive revenue growth. The short cash runway and speculative business model, heavily reliant on pipeline success, outweigh the positive analyst sentiment and projected future profitability. The current price offers no fundamental support given the...
- Persistent unprofitability with negative gross (-0.20781), operating (-0.35047), and net (-0.81728995) margins.
- Significant cash burn with negative operating cash flow (-$97M quarterly, -$485M TTM) and free cash flow (-$98M quarterly, -$494M TTM).
- Negative equity (-$291 million) indicates liabilities exceed assets, signaling a precarious financial position.
Technical team: Neutral
The technical analysis presents a neutral outlook with conflicting signals. While the price is consolidating near support and the layoff news could be a catalyst, bearish moving average signals and overbought momentum indicators suggest caution. A clear directional move is needed to establish conviction.
- Price is consolidating near support, with bearish moving average signals suggesting a potential bounce from support towards the first resistance level if momentum shifts.
- The stock is consolidating near support with low volume, suggesting a neutral outlook until a clear breakout or breakdown occurs.
- Momentum indicators are mixed, with MACD and Stochastic suggesting a potential bearish turn, while RSI remains neutral, and the price is consolidating between support and resistance.
Sentiment team: Neutral
The overall sentiment for Ultragenyx Pharmaceutical (RARE) is neutral, reflecting a balance between positive analyst ratings and potential growth drivers, and concerns regarding its pre-revenue status and recent stock performance. While professional analysts maintain a bullish outlook with significant upside potential, news and social media sentiment are more mixed, creating a stable but unconvincing overall picture.
- Recent news for RARE presents a neutral sentiment, with a slight negative average headline score driven by a single bearish headline about a stock loss, offset by neutral coverage of FDA approvals, potential for gene therapy acceleration, and stock...
- Ultragenyx Pharmaceutical (RARE) shows neutral sentiment with one bearish headline highlighting a recent stock price decline, while positive news points to potential regulatory tailwinds for rare disease therapies, though its pre-revenue status and...
- Ultragenyx Pharmaceutical (RARE) exhibits a neutral sentiment driven by a strong analyst 'Buy' consensus and significant upside potential indicated by price targets, balanced by mixed technical signals, recent institutional net value decrease, and a...
Risk team: High
RARE presents a very high-risk profile due to significant historical drawdowns, negative equity, consistent operating losses, and extreme volatility. While layoffs can signal cost discipline, the underlying financial distress and high short interest suggest substantial headwinds. The potential reward must be weighed against the severe downside risk, necessitating a very small position size.
- Deep Drawdown (1Y): The stock has experienced a significant price decline of over 78% in the past year, indicating substantial investor concerns or negative company-specific events.
- Negative Equity: The company has negative shareholder equity, implying that its liabilities exceed its assets, a critical indicator of financial distress.
- High Realized Volatility: The 60-day annualized volatility is exceptionally high at 104.05%, indicating extreme price fluctuations and difficulty in predicting short-term price movements.
RARE at a glance
| Market value | $1.7B |
| Revenue growth (year over year) | 17.5% |
| Profit margin | -81.7% |
| Debt / equity | 0.00 |
TradeFlare's published calls on RARE
- January 8, 2026: closed after 45 days, -4.6%
Every AI call on RARE since April 21, 2026, and what happened next (1 calls) →
Frequently asked questions
Is RARE a buy? In its research of November 4, 2026, TradeFlare's AI rated RARE a HOLD. This is AI-generated research, not financial advice.
How have TradeFlare's past calls on RARE done? 1 published signal(s), listed above. Every result, win or loss, stays on the public record.
When was this analysis last updated? November 4, 2026. Stocks on TradeFlare's lists are re-researched every market night. How the research works.
Research of November 4, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.